Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has shared an announcement.
Shanghai MicroPort MedBot (Group) Co., Ltd. has obtained approval from China’s National Medical Products Administration for its self-developed UniPath Electronic Bronchoscopic Surgical Robotic System, a non-invasive natural orifice platform designed for early diagnosis and treatment of deep and peripheral pulmonary lesions such as micronodules. The approval lifts the company’s portfolio of approved surgical robot products to seven and makes it, according to the announcement, the first enterprise globally to commercialise a full spectrum of robotic systems across five major and fast-growing surgical specialties, reinforcing its technological depth and signaling a transition toward large-scale development of its domestic surgical robot ecosystem.
The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a China-based medical technology company focused on the research, development and commercialization of surgical robotic systems. The group targets multiple minimally invasive and non-invasive surgical specialties, positioning itself as a domestic leader building a comprehensive surgical robot ecosystem spanning several fast-growing clinical fields.
Average Trading Volume: 3,511,826
Technical Sentiment Signal: Buy
Current Market Cap: HK$21.93B
See more data about 2252 stock on TipRanks’ Stock Analysis page.